Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | ATP4A | P20648 | 1/20 | 0.39 |
| ▸ | ATP4B | P51164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31606366 | 1.00 | CD44 (0.52) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL357603 | 0.85 | GABRA1 (0.48) | CD44TSHRGABRA1GABRG2GABRB3 | |
| SCHEMBL28179325 | 0.85 | TSHR (0.43) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL7760775 | 0.85 | CD44 (0.46) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL3667054 | 0.83 | CD44 (0.54) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL10581584 | 0.83 | CD44 (0.45) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL10581285 | 0.81 | CD44 (0.43) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL30417664 | 0.81 | CD44 (0.52) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL6344760 | 0.81 | CD44 (0.52) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL455161 | 0.81 | CD44 (0.52) | CD44CYP3A4TDP1TSHRPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | claimed |
| US-12486258-B2 | Compounds and methods for regulating insulin secretion | THE BROAD INSTITUTE, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4393937-A1 | STEROID COMPOUND AND CONJUGATE THEREOF | Duality Biologics (Suzhou) Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-114031507-B | Synthesis method of o-aminobenzyl alcohol compound | 辽宁科信生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-110536885-B | Process for producing difluoromethylene compound | 佐藤制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| CN-115057807-B | 3- (2-isocyanobenzyl) indole derivative quorum sensing inhibitor and preparation method and application thereof | 海南大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-115073473-B | Seven-membered ring indoloazepine CYP1B1 enzyme inhibitor, and preparation method and application thereof | 海南大学 | 2023-06-23 | — | — | CN | disclosed |
| US-20230142508-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11555031-B2 | Compounds and methods for regulating insulin secretion | THE BROAD INSTITUTE, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| US-11495755-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2022-11-08 | — | — | US | disclosed |
| WO-1997027193-A1 | IMIDAZOPYRIDINE HALIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-07-31 | — | — | WO | disclosed |
| WO-1996040650-A1 | CYCLIC AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040651-A1 | ALKYL AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0723544-A1 | ALKOXY ALKYL CARBAMATES FROM IMIDAZO (1,2-a)PYRIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010518-A1 | ALKOXY ALKYL CARBAMATES FROM IMIDAZO (1,2-a)PYRIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1995-04-20 | — | — | WO | disclosed |
| EP-0268989-B1 | IMIDAZOPYRIDINE COMPOUNDS AND PROCESSES FOR PREPARATION THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-07-08 | — | — | EP | disclosed |
| US-4920129-A | Anti-ulcerative imidazopyridine compounds | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-04-24 | — | — | US | disclosed |
| US-4831041-A | ANTIULCER AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-05-16 | — | — | US | disclosed |
| EP-0308917-A2 | Imidazopyridine compound, a process for preparation thereof and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-03-29 | — | — | EP | disclosed |
| EP-0268989-A1 | Imidazopyridine compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142508-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | IAPP, GPR119, PNLIP | CD44 2738/4885CYP3A4 4626/4885TDP1 4637/4885 |
| US-11555031-B2 | Compounds and methods for regulating insulin secretion | IAPP, GPR119, INSR | CD44 3841/4885CYP3A4 2639/4885TDP1 4702/4885 |
| US-12486258-B2 | Compounds and methods for regulating insulin secretion | IAPP, GPR119, PNLIP | CD44 2738/4885CYP3A4 4626/4885TDP1 4637/4885 |
| US-11495755-B2 | Organic electroluminescent materials and devices | RUVBL2, TERT, OR10J3 | CD44 3664/4885CYP3A4 2000/4885TDP1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.